

SYSTEMATIC REVIEW

Irradiated patients and survival rate of dental implants: A systematic review and meta-analysis



Adhara Smith Nobrega, DDS,^a Joel Ferreira Santiago, Jr, DDS,^b Daniel Augusto de Faria Almeida, DDS,^c
Daniela Micheline dos Santos, DDS,^d Eduardo Piza Pellizzer, DDS,^e and Marcelo Coelho Goiato, DDS^f

The most common treatment for patients with head and neck cancer is surgery, which may be applied with or without radiotherapy and/or chemotherapy.¹⁻³ Resections from surgical treatment most often result in changes in speech, mastication, and swallowing,⁴ as well as anatomic changes and deformities⁵ such as tissue loss. These changes eventually hinder conventional prosthetic rehabilitation.^{5,6} Thus, individuals with such surgical resections are potential candidates for oral rehabilitation with osseointegrated implants, which improve prosthesis retention and stability and, consequently, function, comfort, esthetics, and quality of life.⁷

However, radiotherapy can change the survival rate (SR) of dental implants, because it reduces the vascularity and regenerative ability of bone tissue. Hypovascularization occurs because increased bone mineral density leads to bone sclerosis,⁸ whereas regenerative ability is affected because osteoblasts and osteocytes,

ABSTRACT

Statement of problem. Radiotherapy has been considered a contraindication for rehabilitation with dental implants because it can change the survival rate of implants. Nevertheless, the installation of implants in irradiated patients has been used with varying success.

Purpose. The purpose of this systematic review was to compare the success rate of implants placed in irradiated human bone tissue with that of implants placed in nonirradiated areas.

Material and methods. Searches were performed in the EMBASE, Cochrane, and PubMed/Medline databases up to December 2013 to identify clinical trials addressing the subject. This systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The relative risks of implant failure and survival curves were calculated considering a confidence interval of 95%. Heterogeneity was analyzed by using a funnel chart.

Results. A total of 40 studies involving 2220 participants and 9231 dental implants were selected. The survival curve of the studies indicated a survival rate of 84.3% for implants installed in irradiated bone tissue. The meta-analysis indicated statistically significant differences ($P < .001$) between item success rates of implants placed in irradiated areas and those of implants placed in nonirradiated areas.

Conclusions. Dental implants installed in the irradiated area of an oral cavity have a high survival rate, but strict monitoring is needed to prevent complications, thereby reducing possible failures. (*J Prosthet Dent* 2016;116:858-866)

bone-forming cells, decrease replicative capacity and bone formation, and osteoclasts, cells responsible for bone resorption, are attracted to the irradiated site. Over time, such events generate an imbalance between bone formation and resorption^{9,10} and a decrease in vascularity associated with a decrease in regenerative ability,

Presented at the Brazilian Society of Dental Research Annual Meeting, São Paulo, Brazil, September 2014.

^aDoctoral student, Department of Dental Materials and Prosthodontics, Aracatuba Dental School, Paulista State University, São Paulo, Brazil.

^bAssistant Professor and Dean of Research and Graduate Studies (PRPPG), Sacred Heart University, Bauru, Brazil.

^cAssistant Professor, Department of Restorative Dentistry, Dental School, Federal University of Alfenas, Minas Gerais, Brazil.

^dAssistant Professor, Aracatuba Dental School, Department of Dental Materials and Prosthodontics, Paulista State University, São Paulo, Brazil.

^eProfessor, Department of Dental Materials and Prosthodontics, Aracatuba Dental School, Paulista State University, São Paulo, Brazil.

^fProfessor, Department of Dental Materials and Prosthodontics, Aracatuba Dental School, Paulista State University, São Paulo, Brazil.

Clinical Implications

Many clinicians consider head and neck radiotherapy to be a risk factor for dental implant placement. However, as many irradiated patients are rehabilitated with implant-supported prostheses, the evaluation of clinical risk is important.

which then affect osseointegration and the longevity of the implants.^{7,9,10}

For such reasons, radiotherapy has been considered a risk factor for this type of rehabilitation.¹¹ Nevertheless, implants with variable SRs have been placed in irradiated patients.^{12,13} This variation can be attributed mainly to the total radiation dose received in the area. Reports^{5,14-19} indicate values of total radiation in the range of 50 to 60 Gy are the borderline values for rehabilitation with dental implants, without the need for additional treatments such as hyperbaric oxygen therapy (HBO).

Published studies are not consistent regarding the optimal time interval between irradiation and surgery for implant placement¹⁰ or for how different doses of radiation affect survival.¹² The purpose of this systematic review was to clarify issues regarding this theme.

The null hypothesis presented in this study was that the SR of implants placed in irradiated bone tissue does not differ from the SR of implants placed in nonirradiated tissue.

MATERIAL AND METHODS

Two independent reviewers (A.S.N., J.F.S.) conducted an electronic review of PubMed/Medline, Cochrane, and EMBASE databases for articles published in English from January 1975 to December 2013. The key words used were "radiotherapy" and "dental implants." The Boolean operators used were ("radiotherapy" [Subheading] OR "radiotherapy"[All Fields] OR "radiotherapy"[MeSH Terms]) AND ("dental implants"[MeSH Terms] OR "dental"[All Fields] AND "implants"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental implant"[All Fields]). A manual search was conducted in review studies addressing the subject. All titles were analyzed, selecting those relevant according to the established criteria.

The initial study selection was directed to the title and abstract analysis. Subsequently, eligible studies were analyzed and included or excluded from the total sample. Randomized controlled trials, prospective, and retrospective studies were included. Thus, the population, intervention, comparison, and outcome (PICO) criteria, as recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) topic guidelines,²⁰

were determined as criteria for questioning to organize a clear clinical question with an appropriate inclusion focus.

The population consisted of patients who required oral rehabilitation with dental implants. The intervention was the installation of implants in irradiated patients, and the comparison was the SR of implants placed in irradiated versus those placed in nonirradiated areas. The outcome was analysis of the SRs and possible indication of implant protocols.

In order to perform the inclusion of studies, the filters selected were human studies in the English language, which contained at least 5 participants who underwent radiotherapy and received dental implants. The studies to be considered also had to report complete data of implant SRs in these regions.

Studies not included were duplicated studies, those describing the surgical technique or focusing on radiotherapy treatment, review, or clinical case studies ($N \leq 5$), studies published more than 20 years ago, articles that did not evaluate the SR of dental implants themselves, and non-peer-reviewed publications. Also excluded were studies considering bone grafting as the most important factor analysis, studies in animals or extraoral implants; studies analyzing mini-implants, periimplantitis, and/or perimucositis; questionnaires about quality of life without considering the longevity of the implants; and studies of participants receiving only chemotherapy or those which focused on histological and histomorphometric analysis. The selection of the 40 studies is presented in [Figure 1](#).

The examiners (A.S.N., J.F.S.) selected the articles in a consensus meeting, and a third examiner (D.A.F.A.) assisted the development of this review. The articles were analyzed and discussed, and possible discrepancies were eliminated by consensus among examiners. The qualities of risk and study limitations were evaluated to eliminate studies that concealed data regarding the SR and possible complications and studies that did not define the success criteria for dental implants.

A Kaplan-Meier test was used to identify the implant survival curve in the analyzed periods and to analyze the SR of the implants installed in the irradiated maxilla or mandible. The risk ratio (RR) with a 95% confidence interval (CI) was used to study only the articles that used the installation of dental implants in the irradiated region and to compare them with those in nonirradiated regions (dichotomous outcome). In all analyses, significant values were considered when the value of P was $< .05$. Software (Reviewer Manager v5.3; Cochrane Group) was used for the meta-analysis and the elaboration of the forest plot and funnel plot.

The random effects model was used in the comparative analysis of implants placed in irradiated and nonirradiated regions. Heterogeneity was considered significant for $P < .1$ and analyzed using the $Q(\chi^2)$ method, and the I^2 value was measured. Data were presented qualitatively, allowing




Figure 1. Flowchart of selected and excluded studies for systematic review.

comparison of the studies analyzed (N=40) and quantitatively in order to study the survival of the implants.

RESULTS

According to the inclusion and exclusion criteria established, 40 articles were selected: 1 randomized, 18 prospective, and 21 retrospective. The total number of participants was 2220, with an average 58 years of age.

Regarding implant locations, 13 studies identified the number of installed implants in the maxilla and mandible.^{1,3-5,13,15,18,19,21-25} A greater number of implants had been installed in the mandible (2185) than in the maxilla (796). The average SR of implants placed in the mandible was higher than the SR of implants placed in the maxilla (Fig. 2).

Irradiated patients received doses ranging from 10 to 145 Gy, and the interval between radiotherapy and implant installation surgery ranged from 1 to 240 months, with an average minimum timeout of 11.82 months. There were also participants for whom radiotherapy was performed after implant installation.^{5,12,24}

A total of 9231 implants were installed in irradiated and nonirradiated participants with variable geometry; the lowest reported diameter was 3.3 mm, and the minimum length was 7.0 mm. The follow-up period from implant placement until the last control of the implant in function ranged from 1 to 276 months.




Figure 2. Analysis of success rate of implants placed in maxilla and mandible.^{1,5,12,13,15,16,18,19,22,24-26}

Of 5562 implants placed in irradiated participants, 862 (15.49%) were classified as failures, whereas 3669 implants were installed in nonirradiated participants with 191 (5.20%) failures. The brand name most used was Nobel Biocare (Table 1).

In quantitative analysis, a total of 5489 implants were placed in irradiated bone tissue regions, and a total of 862 failures were found in a follow-up period of up to 192 months. The Kaplan-Meier analysis indicated an 84.33% SR during the period from 0 to 192 months (Fig. 3). Moreover, as presented in Table 2, the failures occurred in all analyzed periods, but the highest SR reductions occurred after 60 months. The overall results of this review reveal that the percentage of failures tended to increase in patients undergoing radiotherapy, decreasing the SR of these implants.

In a specific analysis of the number of implants that failed during follow-up, statistically significant differences between irradiated and nonirradiated regions that received dental implants were reported in 26 studies. The sum of implant failures revealed 860 implant failures in the irradiated group and 186 implant failures in the nonirradiated group.

In analysis based on random effects, statistically significant differences were observed in the failure of implants placed in irradiated bone tissue (RR: 2.63; 95% CI: 1.93-3.58; $P < .001$) (Fig. 4).

The heterogeneity observed in studies of implant failure outcome was relevant (chi-square: 56.46; $P < .0003$; I^2 : 56%), using the random effects model. The funnel chart indicated a clear symmetry between the differences of the relative risks of the studies analyzed, reducing rates of bias of the study (Fig. 5).

DISCUSSION

This systematic review revealed that the concept of controlled and randomized clinical trials was used only by Schoen et al.³⁹ High financial costs and detailed planning are involved in controlled and randomized clinical trials that use significant numbers of participants undergoing radiotherapy. For this reason, the sample of

included studies basically consisted of retrospective and prospective trials (Table 3), which can be considered biased in this review.

Twelve studies analyzed the SR of implants regarding location.^{1,5,12,13,15,16,18,19,22,24-26} In most of the studies, the SR of implants in the mandible was higher than those in the maxilla (Fig. 2). However, Andersson et al,⁵ Granstrom et al,¹² and Mericske-Stern et al²⁴ found higher SRs in the maxilla. The differences between these results is primarily due to bone quality and vascularization capacity.¹² The mandible presents a more cortical bone, and therefore, obtaining primary stability is easier. However, the greater SR observed in 3 studies in the maxilla can be explained because the maxilla has a more trabecular bone, and hence, greater vascularization, thus favoring the secondary stability of implants.⁴⁴

Four studies did not identify significant differences.^{3,4,21,23} Although they did not provide data about the SR, they did analyze the statistical correlation ($\alpha=.05$) between maxillary and mandibular rates. None showed statistically significant differences for the mandible and maxilla SRs.

The results showed a wide variation in total dosage of radiation received, from 10 to 145 Gy (Table 1), and these values changed according to the purpose of the treatment, location, and diagnosis of the lesion.¹⁷ The treatment consisted of radiotherapy dosages applied in daily fractions of up to 2 Gy, carried out 3 to 5 times per week.^{3,16,23,25}

Even though no article included in this review approached intensity-modulated radiation therapy (IMRT), it is important to highlight this modality, which is a high-precision radiotherapy. IMRT allows high doses of radiation to be applied to the target but with minimum involvement of adjacent tissues. Because this radiotherapy modality damages healthy tissues less, it is mainly indicated for treatment next to structures and/or vital organs, such as in patients with head and neck tumors.^{46,47}

Some studies reached consensus^{5,14,16,18} on the risk of the radiotherapy dose, values of 50 to 60 Gy were predominant. In those situations, the use of HBO would be indicated, because this treatment improves bone repair and assists in the osseointegration process²⁴ by stimulating the irradiated tissues and significantly increasing the oxygen content areas prone to osteoradionecrosis. In the included studies, some authors did not use HBO, explaining that the total radiotherapy dose applied was low.²⁶ In other studies,^{3,29} even with irradiation rates above that range, HBO was not applied as there was no consensus on the need for this treatment.

Some studies^{7,12,13,19,24,37,39,45} used HBO as adjuvant treatment to radiotherapy. Although increases in the SR of irradiated implants could not be verified by some authors,^{13,19,39} significant biases were found in these studies. Niimi et al¹³ claimed that the follow-up period

was not enough to assert that HBO was not required because microvascular circulation decreases over time, whereas the effect of HBO continues for many years. In the studies of Shaw et al¹⁹ and Schoen et al,³⁹ relevant information that could also influence the SR of the implants, such as diameter, length, and surface treatment, was not correlated.

In contrast, other studies^{7,12,45} observed significant improvements in regard to the SRs of implants in the irradiated areas subjected to HBO or as an indication of treatment for osteoradionecrosis.²⁴ The results presented by Granstrom et al⁴⁵ deserve attention. In that study, 4 groups of patients were evaluated, with 1 group consisting of irradiated patients who had lost 34 of 43 implants. After losing implants, such patients underwent treatment with HBO, after which 42 new implants were installed; only 5 were considered failures. Therefore, the success rate rose from 21% to 88.1%, confirming the effectiveness of HBO for this group.

In order to analyze the effectiveness of HBO and answer the possible questions regarding this treatment, a search of high scientific evidence studies, specifically for irradiated patients treated with HBO, was performed. The meta-analysis of Bennett et al⁴⁸ stated that HBO mitigated the effects caused by radiotherapy in the head and neck. However, because of the inclusion of a single study with dental implants, the study did not conclude anything specific on this topic. In contrast, the systematic review of Chambrone et al⁴⁹ addressed implants and stated that HBO did not improve the SR of the implants; in this report, HBO was not the focus of the review, and only 3 studies addressing the issue in question were included. The authors stated that insufficient data were available to support or reject the use of HBO. It appears that there is still no consensus regarding the treatment of irradiated patients also treated with HBO who are rehabilitated with implants. More randomized clinical trials using this treatment to clarify this important issue are suggested.

Another important factor is the waiting period between the last session of radiotherapy and implant surgery. In the present study, this factor varied greatly from 1 to 240 months. However, Table 1 shows that the minimum time adopted by most authors^{2,3,18,23,25} was 6 months. Sammartino et al¹⁸ compared 2 groups of participants: the first had implants installed within a waiting period of less than 12 months, and the second group had implants installed after 12 months. The study found that short waiting periods, less than 12 months, do not guarantee a suitable quality of bone and vascularization, which are factors directly related to osseointegration of the implants. Therefore, the largest number of faults found in the group with placement of implants after radiotherapy is explained. The study of Brasseur et al,⁵⁰ when evaluating the installation of implants in beagle

Table 1. Data of selected studies

| Study year | Study Design | Geographic Region | Participants, n/Mean Age, y | Radiation Dose, Gy | Minimum Waiting Interval, mo | Geometry, mm | Follow-up, mo | Irradiated Bone | Nonirradiated bone | Brand |
|--|---------------|-------------------|-----------------------------|--------------------|------------------------------|--------------|---------------|-----------------------|-----------------------|-----------------------------------|
| | | | | | | | | Implants, n/Failed, n | Implants, n/Failed, n | |
| Al-Nawas et al ²¹ 2012 | Retrospective | Germany | 108/58.8 | - | - | 3.5 | 120 | 87/2 | 429/7 | Astra Tech |
| Andersson et al ⁵ 1998 | Retrospective | Sweden | 15/68 | 44-68 | 8 | 10 | 96 | 90/2 | - | Nobel Biocare |
| August et al ¹⁴ 1998 | Retrospective | U.S. | 18/64 | 65.4 | 44.5 | - | 16.4 | 16/0 | - | - |
| Barrowman et al ⁴ 2011 | Retrospective | Australia | 32/50.7 | - | - | - | 192 | 48/5 | 67/0 | Nobel Biocare |
| Bodard et al ³² 2011 | Retrospective | France | 48/60.2 | 50.2 - 67.5 | 17.2 | 3.3 x 13 | 60 | 232/33 | - | Nobel Biocare, Serf |
| Buddula et al ¹ 2011 | Retrospective | U.S. | 23/46 | 60-65 | - | 3.3 x 13 | 27.5 | 75/6 | - | Nobel Biocare |
| Cao et al ² 2003 | Retrospective | China | 27/52.9 | 36-76 | 6 | - | 60 | 53/9 | 78/11 | Nobel Biocare, Friatec |
| Cuesta-Gil et al ⁶ 2009 | Prospective | Spain | 111/52 | 50-60 | 12 | - | 72 - 108 | 395/48 | 311/4 | Lifecore Biomedical |
| Dholam et al ¹⁷ 2013 | Prospective | India | 30/46 | 20-60 | 12 | - | 60 | 59/10 | 26/0 | - |
| Esser and Wagner ²² 1997 | Retrospective | Germany | 221 | 60 | 9 | 13 | 60 | 221/33 | 71/7 | Nobel Biocare, Friatec |
| Fierz et al ³¹ 2013 | Prospective | Switzerland | 46/57 | 56-61 | - | - | 36 - 72 | 62/14 | 42/4 | - |
| Franzén et al ¹¹ 1995 | Prospective | Sweden | 20 | 25-64 | - | - | 36 - 72 | 20/1 | - | Nobel Biocare |
| Goto et al ²⁶ 2002 | Retrospective | Japan | 36/52.9 | 30 | - | 3.7 x 7 | 2 - 130 | 92/19 | 88/6 | - |
| Granstrom et al ⁴⁵ 1999 | Retrospective | Sweden | 78/64.9 | 25-145 | - | - | 44.2 - 88.8 | 331/126 | 89/12 | Nobel Biocare |
| Granstrom et al ¹² 2005 | Retrospective | Sweden | 207/59.1 | 21-120 | - | - | 6 - 275 | 631/147 | 614/76 | Nobel Biocare |
| Heberer et al ²³ 2011 | Prospective | Germany | 20/61.1 | 72 | 6 | 4.1 x 8 | 14.4 | 102/2 | - | Straumann |
| Jisander et al ¹⁵ 1997 | Prospective | Sweden | 17/67 | 50 | 18 | - | 1 - 62 | 103/5 | - | Nobel Biocare, Astra |
| Keller et al ³⁵ 1997 | Retrospective | U.S. | 19/60 | 60 | - | 3.75 x 8 | 120 | 98/1 | - | Nobel Biocare |
| Korfage et al ³⁶ 2010 | Prospective | Netherlands | 50/61.5 | 12-70 | - | 3.75 | 60 | 123/13 | 72/1 | Nobel Biocare |
| Landés and Kovács ²⁷ 2006 | Prospective | Germany | 30/63 | 57 | 4 | 4.1 x 12 | 24 - 46 | 72/1 | 42/0 | Straumann |
| Linsen et al ³ 2012 | Prospective | Germany | 66/55.7 | 60 | 6 | 10 | 47.99 | 127/8 | 135/6 | - |
| Mancha de la Plata et al ⁷ 2012 | Retrospective | Spain | 30/55.5 | 50-70 | 12 | - | 60 | 225/10 | 130/3 | Osseous-Mozograu |
| McGhee et al ³⁴ 1997 | Prospective | U.S. | 6 | >50 | - | 3.8 x 10 | 12 | 26/4 | - | Sterio OS |
| Mericske-Stern et al ²⁴ 1999 | Retrospective | Switzerland | 17/59.6 | 50-74 | - | 3.4 x 8 | 12 - 84 | 33/4 | 20/0 | Straumann |
| Nelson et al ²³ 2007 | Retrospective | Germany | 93/59 | 72 | 6 | - | 123.6 | 124/7 | 311/4 | Camlog, Nobel, Biocare, Straumann |
| Niimi et al ¹³ 1998 | Prospective | Japan/U.S. | 44 | 66 | 1 | 7 | 49 | 228/20 | - | Nobel Biocare |
| Salinas et al ³⁷ 2010 | Retrospective | U.S. | 44 | 60 | - | 11 | 144 | 90/23 | 116/8 | - |
| Sammartino et al ¹⁸ 2011 | Prospective | Italy | 77/55.8 | 50 | 6 | 8 | - | 172/56 | 16/0 | - |
| Schepers et al ³⁸ 2006 | Retrospective | Netherlands | 61/64.8 | 10-68 | 3 | - | 96 | 61/2 | 78/0 | Nobel Biocare |
| Schliephake et al ²⁶ 1999 | Retrospective | Germany | 83/51.9 | 32-60 | 20 | - | 55.2 | 145/38 | 264/0 | Nobel Biocare |
| Schoen et al ³⁹ 2007 | Randomized | Netherlands | 26/60.1 | 61.4 | - | - | 12 | 103/12 | - | Nobel Biocare |

(continued on next page)

Table 1. Data of selected studies (continued)

| Study year | Study Design | Geographic Region | Participants, n/Mean Age, y | Radiation Dose, Gy | Minimum Waiting Interval, mo | Geometry, mm | Follow-up, mo | Irradiated Bone | Nonirradiated bone | Brand |
|---------------------------------------|---------------|-------------------|-----------------------------|--------------------|------------------------------|--------------|---------------|-----------------------|-----------------------|--|
| | | | | | | | | Implants, n/Failed, n | Implants, n/Failed, n | |
| Schoen et al ⁴² 2008 | Prospective | Netherlands | 50/61.5 | 60 | - | - | 48 | 76/2 | 64/2 | Nobel Biocare |
| Shaw et al ¹⁹ 2005 | Retrospective | United Kingdom | 81/58 | 40-66 | 12 | - | 168 | 172/31 | 192/25 | Friadent, Interpore, International, Nobel Biocare, Imtec |
| Visch et al ¹⁶ 2002 | Prospective | Netherlands | 130/62 | 50 | - | - | 168 | 446/64 | - | Dyna, Screw-vent |
| Wagner et al ²⁹ 1998 | Retrospective | Germany | 63/55 | 60 | 13.02 | - | 65 | 145/5 | 130/0 | Nobel Biocare |
| Watzinger et al ³³ 1996 | Prospective | Austria | 26/62 | 50 | 1 | - | 36 | 136/42 | - | Friatec |
| Weischer and Moher ⁴⁰ 1999 | Prospective | Germany | 40/55 | 50 | 13 | - | 37 | 83/10 | 92/5 | - |
| Weischer et al ³⁰ 1996 | Prospective | Germany | 27 | 36-75 | 13 | - | 26 | 57/4 | 48/3 | Nobel Biocare, Friatec |
| Werkmeister ⁴³ 1999 | Retrospective | Germany | 29/55 | 54 | 24 | - | 18 | 49/14 | 60/5 | - |
| Yerit et al ⁴¹ 2006 | Prospective | Austria | 71/57.8 | 50 | 17 | - | 156 | 154/29 | 84/2 | Straumann, Friatec |
| Total | | | 2 220 | 10-145 | 11.82 | | 1-276 | 5 562/862 | 3 669/191 | |




Figure 3. Survival curve analysis of implants installed in irradiated bone tissue. Survival curve of 84.33% in 192 months.^{1-7,11-17,19,21-43}

dogs before and after radiotherapy, found a better osseointegration, very similar to that in the control, in the group that had implants installed first and then underwent radiation doses. The authors attribute the fact that osseointegration in the previously irradiated implant placement group was not similar to that of the control group to the short time between the end of radiotherapy sessions and implant surgery. However, waiting for osseointegration to install implants and only then applying radiotherapy may be contraindicated, because tumor malignancy and the risk of metastasis requires prompt treatment.

Regarding the geometry of the implant, Goto et al²⁶ observed a greater number of failures in short implants, recommending caution in the use of these implants in irradiated patients. Nevertheless, in the comparative study of Niimi et al,¹³ one group exhibited a higher number of failures in implants of 7 to 10 mm in length, whereas in the second group, most failures occurred in

Table 2. Survival curve analysis of implant installed in region with irradiated bone tissue

| Follow-up Interval, mo | Implants in Each Interval, n* | Failures in Each Interval, n* | Survival Rate Within Each Interval, %* | Cumulative Survival Rate, % |
|------------------------|-------------------------------|-------------------------------|--|-----------------------------|
| 0 | 5489 | 0 | 100 | 100 |
| 0-12 | 5489 | 70 | 98.72 | 98.72 |
| 13-24 | 5419 | 21 | 99.6 | 98.34 |
| 25-36 | 5398 | 95 | 98.29 | 96.61 |
| 37-48 | 5303 | 20 | 99.62 | 96.24 |
| 49-60 | 5283 | 158 | 97 | 93.36 |
| 61-72 | 5125 | 53 | 98.96 | 92.4 |
| 73-84 | 5072 | 4 | 99.92 | 92.33 |
| 85-96 | 5068 | 277 | 94.53 | 87.28 |
| 97-120 | 4791 | 26 | 99.45 | 86.8 |
| 121-160 | 4765 | 36 | 99.24 | 86.15 |
| 161-200 | 4729 | 100 | 97.88 | 84.33 |

*Analysis in period.

implants of 13 to 15 mm in length, suggesting that implant failure can occur regardless of length. However, since this article was published, surface treatments have been developed,¹ and the results may be different. Nevertheless, a current systematic review⁵¹ highlights the view that shorter implants present a greater risk of failure than standard implants, and clinicians must be aware of mechanical and biological care. In this review, a consensus on this issue could not be reached because most of the included studies did not address this information. Future clinical trials should address and analyze such data, as well as the type of implant surface treatment.

Regarding the surface treatment of implants, Buddula et al¹ analyzed a single brand of implants. However,




Figure 4. Comparison of implants installed in irradiated and nonirradiated bone. Outcome, implant failure. CI, confidence interval; *df* = degree of freedom.




Figure 5. Funnel plot for publication bias assessment. All studies were used.

one group used machined implants and another used surface treatment implants. They verified that the machined implants tended to fail 2.9 times more than the implants with surface treatment. The properties of the implant surfaces, such as topography and chemical

Table 3. Comparative assessment of methodological quality for 40 studies selected

| Studies (ref. number) | Study Design | Mean Sample Size of Patients | Mean No. of Implants | Mean Periods of Follow-up, mo |
|--|---------------|------------------------------|----------------------|-------------------------------|
| 1,2,4,5,7,12,14,19, 21,22,24-26,28,29, 32,35,37,38,43,45 | Retrospective | 63 | 268 | 105.1 |
| 3,6,11,13,15,18,23,27, 30,31,33,34,36,40-42 | Prospective | 48 | 192 | 59.7 |
| 39 | Randomized | 26 | 103 | 12 |

Studies grouped according to resemblances in their methodology.

treatment,²³ are important factors. In addition to providing greater contact between the bone and the implant, especially in areas of less corticalized bone tissue, which favors biological responses that accelerate the osseointegration process, surface treatments also increase mechanical strength and reduce corrosion.^{52,53} The diversity of brands of implants tested is shown in Table 1. However, few studies^{7,12,19,21,23,25,36} specified the brand of implants placed, and the authors did not correlate the implant SR when different types were used in the same study, the only exceptions being Buddula et al,¹ Landes and Kovacs,²⁷ and

Nelson et al.²⁵ Some of the studies^{3,14,17,18,26,31,37,40,43} did not even identify the brand of implants.

The main outcome of the present study was that the success rate of implants placed in irradiated tissue was lower than that of implants placed in nonirradiated tissue ($P<.001$); thus, the null hypothesis was rejected. Homogeneity was noted in the included studies, which showed a lower SR in irradiated sites (Fig. 4). The only exception was the retrospective study of Al-Nawas et al,²¹ where results showed that the risk of implant loss in nonirradiated patients was higher than in irradiated patients. The authors²¹ attributes such results to the use of bone grafts and also to the bias of the study, which presented a small number of participants undergoing radiotherapy compared with the total number of participants.

The lowest SR in irradiated sites is explained in the study of Verdonck et al,⁴⁴ where, although the primary stability of implants in irradiated and nonirradiated sites was very similar, the secondary stability of implants in irradiated areas was damaged over time. This difference is because the primary stability depends only on the bone density where the implant was installed, whereas secondary stability, which is related to osseointegration effectiveness, depends on bone remodeling that is directly linked to vascularization. Some studies,^{2,4,5,7,9,10,21} despite having cited some complications like periimplantitis and osteonecrosis, did not give due relevance to the question, the exception being Granstrom et al.⁴⁵ Complications in such patients can have serious consequences, for which, at times, no possible treatment is available.

Finally, this study supports the predictability of dental implants in irradiated patients, because it can improve the quality of life for patients and can facilitate social rehabilitation. A strict treatment protocol with detailed periodic monitoring by the dentist, including occlusal adjustments, contact points, radiographic follow-up, and cleaning techniques, should be performed. However, to establish a protocol of treatment, the waiting interval, the dose risk, and the most appropriate geometries of implants for irradiated patients, new studies must be conducted as randomized and double-blind trials.

CONCLUSIONS

Although the results of this meta-analysis state that the favorable SR of implants installed in irradiated areas is 85% after 16 years of follow-up, only a few studies performed a lengthy follow-up, which may be a bias of this result. This study concluded that dental implants placed in irradiated areas have a lower SR than those installed in nonirradiated areas, and possible complications are a high-risk threat throughout the life of these patients. Close monitoring is necessary to avoid complications and reduce the chances of failure.

REFERENCES

- Buddula A, Assad DA, Salinas TJ, Garces YI, Volz JE, Weaver AL. Survival of turned and roughened dental implants in irradiated head and neck cancer patients: a retrospective analysis. *J Prosthet Dent* 2011;106:290-6.
- Cao Y, Weischer T. Comparison of maxillary implant-supported prosthesis in irradiated and non-irradiated patients. *J Huazhong Univ Sci Technolog Med Sci* 2003;23:209-12.
- Linsen SS, Martini M, Stark H. Long-term results of endosteal implants following radical oral cancer surgery with and without adjuvant radiation therapy. *Clin Implant Dent Relat Res* 2012;14:250-8.
- Barrowman RA, Wilson PR, Wiesenfeld D. Oral rehabilitation with dental implants after cancer treatment. *Aust Dent J* 2011;56:160-5.
- Andersson G, Andreasson L, Bjelkengren G. Oral implant rehabilitation in irradiated patients without adjunctive hyperbaric oxygen. *Int J Oral Maxillofac Implants* 1998;13:647-54.
- Cuesta-Gil M, Ochandiano Caicoya S, Riba-Garcia F, Duarte Ruiz B, Navarro Cuellar C, Navarro Vila C. Oral rehabilitation with osseointegrated implants in oncologic patients. *J Oral Maxillofac Surg* 2009;67:2485-96.
- Mancha de la Plata M, Gias LN, Diez PM, Muñoz-Guerra M, González-García R, Lee GY, et al. Osseointegrated implant rehabilitation of irradiated oral cancer patients. *J Oral Maxillofac Surg* 2012;70:1052-63.
- Verdonck HW, Meijer GJ, Nieman FH, Stoll C, Riediger D, de Baat C. Quantitative computed tomography bone mineral density measurements in irradiated and non-irradiated minipig alveolar bone: an experimental study. *Clin Oral Implants Res* 2008;19:465-8.
- Bolind P, Johansson CB, Johansson P, Granstrom G, Albrektsson T. Retrieved implants from irradiated sites in humans: a histologic/histomorphometric investigation of oral and craniofacial implants. *Clin Implant Dent Relat Res* 2006;8:142-50.
- Brognez V, Lejoste P, Pecheur A, Reyckler H. Dental prosthetic reconstruction of osseointegrated implants placed in irradiated bone. *Int J Oral Maxillofac Implants* 1998;13:506-12.
- Franzen L, Rosenquist JB, Rosenquist KI, Gustafsson I. Oral implant rehabilitation of patients with oral malignancies treated with radiotherapy and surgery without adjunctive hyperbaric oxygen. *Int J Oral Maxillofac Implants* 1995;10:183-7.
- Granstrom G. Osseointegration in irradiated cancer patients: an analysis with respect to implant failures. *J Oral Maxillofac Surg* 2005;63:579-85.
- Niimi A, Ueda M, Keller EE, Worthington P. Experience with osseointegrated implants placed in irradiated tissues in Japan and the United States. *Int J Oral Maxillofac Implants* 1998;13:407-11.
- August M, Bast B, Jackson M, Perrott D. Use of the fixed mandibular implant in oral cancer patients: a retrospective study. *J Oral Maxillofac Surg* 1998;56:297-301.
- Jisander S, Grenthe B, Alberius P. Dental implant survival in the irradiated jaw: a preliminary report. *Int J Oral Maxillofac Implants* 1997;12:643-8.
- Visch LL, van Waas MA, Schmitz PI, Levendag PC. A clinical evaluation of implants in irradiated oral cancer patients. *J Dent Res* 2002;81:856-9.
- Dholam KP, Pusalkar HA, Yadav PS, Quazi GA, Somani PP. Implant-retained dental rehabilitation in head and neck cancer patients: an assessment of success and failure. *Implant Dent* 2013;22:604-9.
- Sammartino G, Marenzi G, Cioffi I, Tete S, Mortellaro C. Implant therapy in irradiated patients. *J Craniofac Surg* 2011;22:443-5.
- Shaw RJ, Sutton AF, Cawood JI, Howell RA, Lowe D, Brown JS, et al. Oral rehabilitation after treatment for head and neck malignancy. *Head Neck* 2005;27:459-70.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8:336-41.
- Al-Nawas B, Kammerer PW, Morbach T, Ladwein C, Wegener J, Wagner W. Ten-year retrospective follow-up study of the TiOblast dental implant. *Clin Implant Dent Relat Res* 2012;14:127-34.
- Esser E, Wagner W. Dental implants following radical oral cancer surgery and adjuvant radiotherapy. *Int J Oral Maxillofac Implants* 1997;12:552-7.
- Heberer S, Kilic S, Hossamo J, Raguse JD, Nelson K. Rehabilitation of irradiated patients with modified and conventional sandblasted acid-etched implants: preliminary results of a split-mouth study. *Clin Oral Implants Res* 2011;22:546-51.
- Mericske-Stern R, Perren R, Raveh J. Life table analysis and clinical evaluation of oral implants supporting prostheses after resection of malignant tumors. *Int J Oral Maxillofac Implants* 1999;14:673-80.
- Nelson K, Heberer S, Glatzer C. Survival analysis and clinical evaluation of implant-retained prostheses in oral cancer resection patients over a mean follow-up period of 10 years. *J Prosthet Dent* 2007;98:405-10.
- Goto M, Jin-Nouchi S, Ihara K, Katsuki T. Longitudinal follow-up of osseointegrated implants in patients with resected jaws. *Int J Oral Maxillofac Implants* 2002;17:225-30.
- Landes CA, Kovacs AF. Comparison of early telescope loading of non-submerged III implants in irradiated and non-irradiated oral cancer patients. *Clin Oral Implants Res* 2006;17:367-74.

28. Schliephake H, Neukam FW, Schmelzeisen R, Wichmann M. Long-term results of endosteal implants used for restoration of oral function after oncologic surgery. *Int J Oral Maxillofac Surg* 1999;28:260-5.
29. Wagner W, Esser E, Ostkamp K. Osseointegration of dental implants in patients with and without radiotherapy. *Acta Oncol* 1998;37:693-6.
30. Weischer T, Schettler D, Mohr C. Concept of surgical and implant-supported prostheses in the rehabilitation of patients with oral cancer. *Int J Oral Maxillofac Implants* 1996;11:775-81.
31. Fierz J, Hallermann W, Mericske-Stern R. Patients with oral tumors. Part 1: Prosthetic rehabilitation following tumor resection. *Schweiz Monatsschr Zahnmed* 2013;123:91-105.
32. Bodard AG, Bemer J, Gourmet R, Lucas R, Coroller J, Salino S, et al. Dental implants and free fibula flap: 23 patients. *Rev Stomatol Chir Maxillofac* 2011;112:e1-4.
33. Watzinger F, Ewers R, Henninger A, Sudasch G, Babka A, Woelfl G. Endosteal implants in the irradiated lower jaw. *J Craniomaxillofac Surg* 1996;24:237-44.
34. McGhee MA, Stern SJ, Callan D, Shewmake K, Smith T. Osseointegrated implants in the head and neck cancer patient. *Head Neck* 1997;19:659-65.
35. Keller EE, Tolman DE, Zuck SL, Eckert SE. Mandibular endosseous implants and autogenous bone grafting in irradiated tissue: a 10-year retrospective study. *Int J Oral Maxillofac Implants* 1997;12:800-13.
36. Korfage A, Schoen PJ, Raghoobar GM, Roodenburg JL, Vissink A, Reintsema H. Benefits of dental implants installed during ablative tumour surgery in oral cancer patients: a prospective 5-year clinical trial. *Clin Oral Implants Res* 2010;21:971-9.
37. Salinas TJ, Desa VP, Katsnelson A, Miloro M. Clinical evaluation of implants in radiated fibula flaps. *J Oral Maxillofac Surg* 2010;68:524-9.
38. Schepers RH, Slagter AP, Kaanders JH, van den Hoogen FJ, Merckx MA. Effect of postoperative radiotherapy on the functional result of implants placed during ablative surgery for oral cancer. *Int J Oral Maxillofac Surg* 2006;35:803-8.
39. Schoen PJ, Raghoobar GM, Bouma J, Reintsema H, Vissink A, Sterk W, et al. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: effects of hyperbaric oxygen therapy. *Oral Oncol* 2007;43:379-88.
40. Weischer T, Mohr C. Ten-year experience in oral implant rehabilitation of cancer patients: treatment concept and proposed criteria for success. *Int J Oral Maxillofac Implants* 1999;14:521-8.
41. Yerit KC, Posch M, Seemann M, Hainich S, Dörtbudak O, Turhani D, et al. Implant survival in mandibles of irradiated oral cancer patients. *Clin Oral Implants Res* 2006;17:337-44.
42. Schoen PJ, Raghoobar GM, Bouma J, Reintsema H, Burlage FR, Roodenburg JL, et al. Prosthodontic rehabilitation of oral function in head-neck cancer patients with dental implants placed simultaneously during ablative tumour surgery: an assessment of treatment outcomes and quality of life. *Int J Oral Maxillofac Surg* 2008;37:8-16.
43. Werkmeister R, Szulcowski D, Walteros-Benz P, Joos U. Rehabilitation with dental implants of oral cancer patients. *J Craniomaxillofac Surg* 1999;27:38-41.
44. Verdonck HW, Meijer GJ, Laurin T, Nieman FH, Stoll C, Riediger D, et al. Implant stability during osseointegration in irradiated and non-irradiated minipig alveolar bone: an experimental study. *Clin Oral Implants Res* 2008;19:201-6.
45. Granstrom G, Tjellstrom A, Branemark PI. Osseointegrated implants in irradiated bone: a case-controlled study using adjunctive hyperbaric oxygen therapy. *J Oral Maxillofac Surg* 1999;57:493-9.
46. Kaviarasu K, Raj NA, Murthy KK, Babu AA, Prasad BL. Impact of dose rate on accuracy of intensity modulated radiation therapy plan delivery using the pretreatment portal dosimetry quality assurance and setting up the workflow at hospital levels. *J Med Phys* 2015;40:226-32.
47. Vallard A, Guy JB, Mengue Ndong S, Vial N, Rivoirard R, Auberdiac P, et al. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry. *Head Neck* 2016;38:1028-34.
48. Bennett MH, Feldmeier J, Hampson N, Smees R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. *Cochrane Database Syst Rev* 2012;5:Cd005005.
49. Chambrone L, Mandia J Jr, Shibli JA, Romito GA, Abrahao M. Dental implants installed in irradiated jaws: a systematic review. *J Dent Res* 2013;92:119-30.
50. Brasseur M, Brogniez V, Grégoire V, Reyckher H, Lengelé B, D'Hoore W, et al. Effects of irradiation on bone remodelling around mandibular implants: an experimental study in dogs. *Int J Oral Maxillofac Surg* 2006;35:850-5.
51. Lemos CA, Ferro-Alves ML, Okamoto R, Mendonça MR, Pellizzer EP. Short dental implants versus standard dental implants placed in the posterior jaws: a systematic review and meta-analysis. *J Dent* 2016;47:8-17.
52. Tavares MG, de Oliveira PT, Nanci A, Hawthorne AC, Rosa AL, Xavier SP. Treatment of a commercial, machined surface titanium implant with H2SO4/H2O2 enhances contact osteogenesis. *Clin Oral Implants Res* 2007;18:452-8.
53. Wennerberg A, Albrektsson T. Effects of titanium surface topography on bone integration: a systematic review. *Clin Oral Implants Res* 2009;20:172-84.

Corresponding author:

Dr Marcelo Coelho Goiato
 Aracatuba Dental School (UNESP)
 Department of Dental Materials and Prosthodontics
 José Bonifácio, 1193-Vila Mendonça
 Araçatuba, SP
 BRAZIL
 Email: goiato@foa.unesp.br

Copyright © 2016 by the Editorial Council for *The Journal of Prosthetic Dentistry*.